Cue Biopharma shares surge on positive mid-stage study results for CUE-221
Cue Biopharma shares soared 28.9% in premarket trading after the company announced positive results from its mid-stage study for CUE-221 in hives treatment. The company stated that the phase 2 primary and key secondary endpoints were met. Earlier in the month, Cue Biopharma reported that its Q2 revenue more than double